BIIB

Biogen
D

BIIB

142.700
USD
1.76
(1.25%)
مفتوح الان
حجم التداول
8,248
الربح لكل سهم
17
العائد الربحي
-
P/E
13
حجم السوق
20,758,448,580
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -2.980
    (-1.73%)
    169.560 USD
    AMGN
    AMGN
    -1.01
    (-0.37%)
    273.94 USD
    GILD
    GILD
    -0.530
    (-0.57%)
    92.420 USD
    REGN
    REGN
    7.35
    (1.07%)
    694.67 USD
    SNY
    SNY
    -0.110
    (-0.21%)
    51.560 USD
    TAK
    TAK
    -0.080
    (-0.61%)
    13.025 USD
    المزيد
الأخبار
المقالات

العنوان: Biogen

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.